Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-valent pneumococcal conjugate vaccine phase 1/2 trial in adults and elderly
CTR20220318Phase 2Completed
- Sponsor
- Kunli Biopharmaceutical
- Start
- Feb 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Reinovax PCV24 in invasive pneumococcal disease (IPD), sponsored by Kunli Biopharmaceutical. Started Feb 2022; status: completed.
02
Drugs
Reinovax PCV24
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on CTR20220318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220318.